Session Type: Poster Session
Date: Tuesday, May 5, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Introduction: Hepatocellular cancer (HCC) is a common indication for transplantation. Eovist (gadolinium-EOB-DTPA), compared to conventional gadolinium-enhanced MRI (MRI-Gd) or triple-phase contrast-enhanced computed tomography (CT), is considered a superior method for detection of hepatocellular cancer (HCC) due to its near 50% hepatobiliary excretion. In patients with cirrhosis, Eovist enhances lesion-to-liver contrast and differentiates vascular shunts and dysplastic nodules from HCC, an important distinction as outcomes of transplantation depend on the degree of cancer burden. We investigate whether MRI with Eovist (MRI-E) enables more accurate evaluation of HCC compared to MRI-Gd or CT.
Methods: A retrospective analysis of all patients with HCC undergoing liver transplantation at Cedars-Sinai Medical Center from 2009-2014 was conducted. Multicentric tumors were included if they could be uniquely identified across modalities based on anatomic location. Number and size of lesions measured by MRI-E, MRI-Gd, or CT were compared to explant pathology using repeated measures ANOVA and linear regression analysis. Viability on imaging vs. pathology was compared using chi-squared tests.
Results: Sixty-four patients with 137 HCC tumors were imaged with MRI-E (n=96), MRI-Gd (n=63), and/or CT (n=53); 33 tumors were measured with all 3 modalities. The number of lesions identified was equivalent by pathology or MRI-E, which were significantly higher than the number detected by MRI-Gd or CT (p<.05). All three imaging modalities significantly underestimated maximum tumor diameter relative to pathology (p=.0003). Maximum tumor diameter by MRI-Gd had significantly stronger correlation with pathology than MRI-E or CT (p=.008). MRI-E (χ2=3.52, p=.061) and CT (χ2=3.57, p=.059) were better at assessing viability than MRI-Gd (χ2=1.22, p=.268).
Conclusions: This is the first study to compare imaging of HCC using MRI-E, MRI-Gd, or CT to explant pathology. All three modalities tend to underestimate the burden of disease. MRI with Eovist is a useful adjunct for liver transplant candidacy evaluation with superior assessment of the number of HCC lesions, but it may have limited precision when assessing lesion size. With the scarcity of organs available for liver transplant, there is still room for improvement in imaging modalities in estimating tumor burden.
To cite this abstract in AMA style:Chen M, Reich H, Uffenheimer M, Nasseri Y, Annamalai A. Advanced Imaging Modalities for Hepatocellular Carcinoma: Is MRI With Eovist Really Better? [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/advanced-imaging-modalities-for-hepatocellular-carcinoma-is-mri-with-eovist-really-better/. Accessed December 1, 2023.
« Back to 2015 American Transplant Congress